Politico: Brand-Name, Generic Drugmakers Fight FTC
Brand and generic drug companies are usually at each other' throats. But they will stand shoulder to shoulder against the Federal Trade Commission and other health care interests come March 25, when the Supreme Court will hear oral arguments about a controversial way of settling patent disputes that’s worth billions to the drug industry (Norman, 3/12).
This is part of Kaiser Health News' Daily Report - a summary of health policy coverage from more than 300 news organizations. The full summary of the day's news can be found here and you can sign up for e-mail subscriptions to the Daily Report here. In addition, our staff of reporters and correspondents file original stories each day, which you can find on our home page.